Tecan Group AG/€TECN

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Tecan Group AG

Tecan Group AG is a Swiss company specializing in laboratory instruments and solutions within the life sciences sector. The company offers a range of automated workflow and instrumentation solutions for laboratories involved in diagnostics, bio-pharmaceuticals, and forensics. Founded in 1980 and headquartered in Männedorf, Switzerland, Tecan operates globally, serving clients across various continents. The company's strategic positioning lies in its emphasis on automation and high-throughput systems, which cater to the growing demand for efficiency in laboratory settings. Tecan's products are characterized by their precision and adaptability, allowing for integration into diverse laboratory environments.

Ticker

€TECN
Sector

Primary listing

XGAT

Employees

3,000

Headquarters

Männedorf, Switzerland

Tecan Group AG Metrics

BasicAdvanced
€2.2B
31.90
€5.32
0.93
€3.24
0.95%

Bulls say / Bears say

Tecan’s Q2 2025 order intake returned to growth in the mid-single digits, and the book-to-bill ratio for H1 climbed above 1, indicating recovering demand and an improving backlog (Reuters)
Tecan announced a CHF 120 million share buyback—amounting to 6% of share capital—demonstrating management’s confidence in long-term business prospects and the company’s robust financial position (Reuters)
Monica Manotas, who spent 24 years at Thermo Fisher Scientific, took over as CEO effective August 1, 2025, bringing deep life-sciences experience and leadership aimed at driving innovation and growth (Reuters)
H1 sales fell 5.9% in Swiss francs, highlighting continued pressure on revenue as demand remained soft in both Life Sciences and Partnering divisions, despite cost-cutting measures (Reuters)
Tecan’s EBIT margin dropped to a historic low of 5.3% in H1 2025, impacted by foreign exchange fluctuations, U.S. tariffs, and weak Life Sciences instrument sales (Reuters)
While Waters Corporation increased the lower end of its 2025 profit forecast thanks to strong biotech demand, Tecan’s guidance signals between a mid-single-digit sales decline and low-single-digit growth, with EBITDA falling short of consensus estimates and suggesting the risk of losing market share (Reuters, Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy €TECN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs